Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $12.31, for a total value of $24,620.00. Following the completion of the transaction, the president now owns 2,831,260 shares in the company, valued at approximately $34,852,810.60. This represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total value of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total value of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total value of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total value of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total value of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total value of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.

Gyre Therapeutics Stock Up 1.4 %

Shares of NASDAQ:GYRE traded up $0.17 during mid-day trading on Monday, reaching $12.28. 75,700 shares of the stock were exchanged, compared to its average volume of 74,132. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $19.00. The stock’s 50 day simple moving average is $11.27 and its 200-day simple moving average is $12.30.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC acquired a new position in Gyre Therapeutics in the 3rd quarter valued at $47,000. Wells Fargo & Company MN lifted its position in shares of Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after buying an additional 913 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares during the last quarter. Barclays PLC lifted its position in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after buying an additional 1,389 shares during the last quarter. 23.99% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Noble Financial began coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating for the company.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.